¼¼°èÀÇ Áö¹æ°£ Ä¡·á ½ÃÀå
Fatty Liver Treatment
»óǰÄÚµå : 1757725
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 285 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,053,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,161,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Áö¹æ°£ Ä¡·á ¼¼°è ½ÃÀåÀº 2030³â±îÁö 231¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2024³â¿¡ 187¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Áö¹æ°£ Ä¡·á ¼¼°è ½ÃÀåÀº 2024-2030³â ºÐ¼® ±â°£ µ¿¾È CAGR 3.6%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 231¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Ä¡¾ÆÁ¹¸®µòµð¿ÂÀº CAGR 3.0%¸¦ ±â·ÏÇÏ¸ç ºÐ¼® ±â°£ Á¾·á½Ã¿¡´Â 66¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ºñŸ¹Î E ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 2.8%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 51¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ÇÑÆí Áß±¹Àº CAGR 6.5%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ´Â

¹Ì±¹ÀÇ Áö¹æ°£ Ä¡·á ½ÃÀåÀº 2024³â¿¡´Â 51¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 46¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 6.5%¸¦ ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±âŸ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ªº° ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖ°í, ºÐ¼® ±â°£ µ¿¾È CAGRÀº °¢°¢ 1.5%¿Í 2.7%·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 2.0%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°èÀÇ Áö¹æ°£ Ä¡·á ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

Áö¹æ°£ ÁúȯÀÌ Àü ¼¼°è º¸°Ç ¹®Á¦·Î ´ëµÎµÇ°í ÀÖ´Â ÀÌÀ¯´Â ¹«¾ùÀ̸ç, Ç¥Àû Ä¡·á°¡ ÇÊ¿äÇÑ ÀÌÀ¯´Â ¹«¾ùÀϱî?

ºñ¾ËÄڿüº Áö¹æ°£Áúȯ(NAFLD)°ú ¾ËÄڿüº Áö¹æ°£Áúȯ(AFLD)À» Æ÷ÇÔÇÑ Áö¹æ°£ÁúȯÀº À¯º´·ü Áõ°¡, ´ë»çÀå¾Ö¿ÍÀÇ ¹ÐÁ¢ÇÑ ¿¬°ü¼º, Áö¹æ°£¿°, ¼¶À¯Áõ, °£°æº¯Áõ, °£¼¼Æ÷¾Ï µî ´õ ½É°¢ÇÑ °£ÁúȯÀ¸·Î ÁøÇàµÉ °¡´É¼ºÀ¸·Î ÀÎÇØ Àü ¼¼°èÀûÀ¸·Î ½É°¢ÇÑ °øÁߺ¸°Ç ¹®Á¦·Î ´ëµÎµÇ°í ÀÖ½À´Ï´Ù. À§»ý ¹®Á¦·Î ´ëµÎµÇ°í ÀÖ½À´Ï´Ù. Çö´ëÀÎÀÇ ÁÂ½Ä »ýȰ½À°ü, ½Ä»ýȰÀÇ º¯È­, ºñ¸¸À²ÀÇ Áõ°¡, Á¦2Çü ´ç´¢º´ÀÇ À¯º´·ü Áõ°¡ µîÀº Áö¹æ°£, ƯÈ÷ NAFLDÀÇ ³î¶ó¿î Áõ°¡ÀÇ ¿øÀÎÀÌ µÇ°í ÀÖÀ¸¸ç, ÇöÀç Àü ¼¼°è Àα¸ÀÇ 25%°¡ NAFLD¸¦ ¾Î°í ÀÖÀ¸¸ç, NAFLD´Â Àü ¼¼°è Àα¸ÀÇ 25%°¡ ¾Î°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ À¯º´·ü¿¡µµ ºÒ±¸Çϰí, Áö¹æ°£ ÁúȯÀº Ãʱ⿡´Â Áõ»óÀÌ ¾ø¾î Áø´ÜµÇÁö ¾Ê°í ¹æÄ¡µÇ´Â °æ¿ì°¡ ¸¹À¸¸ç, °³ÀÔ ¾øÀÌ ÁøÇàµÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. µû¶ó¼­ »ýȰ½À°ü °³¼± ÇÁ·Î±×·¥À̳ª ¾à¸®ÇÐÀû ÁßÀçºÎÅÍ ÁßÁõÀÎ °æ¿ì ¼ö¼úÀû ÇØ°á¿¡ À̸£±â±îÁö È¿°úÀûÀÎ Ä¡·á¹ýÀÇ °³¹ß ¹× ½ÃÇàÀÌ ½Ã±ÞÇÑ ½ÇÁ¤ÀÔ´Ï´Ù. ¶ÇÇÑ, Áö¹æ°£ Áúȯ°ú ½ÉÇ÷°ü ÇÕº´Áõ »çÀÌÀÇ ÀáÀçÀûÀÎ ¿¬°ü¼ºÀ¸·Î ÀÎÇØ ±× ÀÇÇÐÀû Á߿伺ÀÌ ´õ¿í Ä¿Áö°í ÀÖÀ¸¸ç, ±× Ä¡·á´Â °£ °Ç°­¿¡ ÇʼöÀûÀϻӸ¸ ¾Æ´Ï¶ó ´õ ±¤¹üÀ§ÇÑ Àü½ÅÀû À§ÇèÀ» ÁÙÀÌ´Â µ¥¿¡µµ Áß¿äÇÕ´Ï´Ù. ÀÓ»óÀÇ¿Í È¯ÀÚ ¸ðµÎÀÇ ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó Á¶±â Áø´Ü°ú ȯÀÚº° ¸ÂÃã Ä¡·á Àü·«Àº Áúº´ÀÇ ÁøÇàÀ» ´ÊÃß°í ¸¸¼º °£ÁúȯÀ¸·Î ÀÎÇÑ Àå±âÀûÀÎ °Ç°­°ü¸® ºÎ´ãÀ» ÁÙÀÌ´Â µ¥ ÀÖ¾î ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù.

Ä¡·á Çõ½ÅÀÌ Áö¹æ°£ Áúȯ °ü¸®¸¦ ¾î¶»°Ô º¯È­½Ã۰í Àִ°¡?

ÀÇÇÐ ¿¬±¸¿Í ÀǾàǰ °³¹ßÀÇ ¹ßÀüÀº º¸´Ù È¿°úÀûÀÎ Áúº´ °ü¸®¿Í Àå±âÀûÀÎ °á°ú¿¡ ´ëÇÑ Èñ¸ÁÀ» °¡Á®´ÙÁÖ¸ç °£ ÁúȯÀÇ »óȲÀ» ºü¸£°Ô º¯È­½Ã۰í ÀÖ½À´Ï´Ù. ÀüÅëÀûÀ¸·Î ½Ä½À°ü °³¼±, ¿îµ¿·® Áõ°¡, üÁß °¨·®°ú °°Àº »ýȰ½À°ü °³¼±Àº Áö¹æ°£ Áúȯ¿¡ ´ëÇÑ 1Â÷ ¹æ¾î¼± ¿ªÇÒÀ» ÇØ¿Ô½À´Ï´Ù. ±×·¯³ª ȯÀÚµéÀÇ ¼øÀÀµµÀÇ ÇѰè¿Í ÀϰüµÈ Ä¡·á ¼º°úÀÇ ºÎÁ·À¸·Î ÀÎÇØ ¾à¸®ÇÐÀû ÇØ°áÃ¥À» ¸ð»öÇÏ´Â ¿òÁ÷ÀÓÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ÇöÀç ÁöÁú´ë»ç, ¿°Áõ, ¼¶À¯Áõ, Àν¶¸° ÀúÇ×¼ºÀÇ ÁÖ¿ä ±âÀüÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â ¿©·¯ ¾à¹° Èĺ¸¹°ÁúÀÌ ÀÓ»ó½ÃÇè Áß¿¡ ÀÖÀ¸¸ç, FXR ÀÛ¿ëÁ¦, PPAR ÀÛ¿ëÁ¦, GLP-1 ¼ö¿ëü ÀÛ¿ëÁ¦ µîÀÌ Æ÷ÇԵ˴ϴÙ. ÇÇ¿À±Û¸®Å¸Á¸À̳ª ºñŸ¹Î E¿Í °°Àº ¾à¹°Àº ƯÁ¤ ȯÀÚ ÇÏÀ§ ±×·ì¿¡¼­ Á¡ÁøÀûÀÎ ¼º°øÀ» º¸À̰í ÀÖÀ¸¸ç, ¿Àº£Æ¼ÄÝ»êÀ̳ª ·¹½º¸ÞƼ·Ò°ú °°Àº »õ·Î¿î ¾à¹°Àº NASH(ºñ¾ËÄڿüº Áö¹æ°£¿°) ȯÀÚÀÇ °£ Áö¹æ·®°ú ¼¶À¯Áõ °¨¼Ò¿¡ À¯¸ÁÇÑ °á°ú¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ´ÜÀÏÁ¦ Ä¡·á¿Í ´õºÒ¾î ¿©·¯ º´Å»ý¸® °æ·Î¸¦ µ¿½Ã¿¡ ´Ù·ç´Â º´¿ë¿ä¹ýÀÌ º¸´Ù È¿°úÀûÀÎ Ä¡·á¹ýÀ¸·Î ÁÖ¸ñ¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, FibroScan, MRI-PDFF, Ç÷û ¹ÙÀÌ¿À¸¶Ä¿¿Í °°Àº ºñħ½ÀÀû Áø´Ü µµ±¸ÀÇ ÅëÇÕÀ¸·Î Ä¡·á ¸ð´ÏÅ͸µÀÌ °­È­µÇ¾î °³ÀÎÈ­µÈ Ä¡·á °èȹÀ» ¼ö¸³ÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ¶ÇÇÑ, µðÁöÅÐ °Ç°­ µµ±¸¿Í ¸ð¹ÙÀÏ °Ç°­ ¾ÛÀº Çൿ ÃßÀû ¹× ¿ø°ÝÀÇ·á Áö¿øÀ» ÅëÇØ ȯÀÚ°¡ »ýȰ½À°ü º¯È­¸¦ À¯ÁöÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Ä¡·á Çõ½ÅÀº ÀÓ»ó °á°ú¸¦ °³¼±ÇÒ »Ó¸¸ ¾Æ´Ï¶ó Áö¹æ°£ Ä¡·á¸¦ º¸´Ù Á¢±ÙÇϱ⠽±°í, ±Ù°Å¿¡ ±â¹ÝÇϸç, ȯÀÚº° »óÅ¿¡ ¸Â°Ô Á¶Á¤ÇÒ ¼ö ÀÖµµ·Ï µ½°í ÀÖ½À´Ï´Ù.

Áö¹æ°£ Ä¡·áÀÇ ¼ö¿ä°¡ Àα¸Åë°è¿Í Áö¿ªÀ» ºÒ¹®Çϰí Áõ°¡ÇÏ´Â ÀÌÀ¯´Â ¹«¾ùÀϱî?

Àü ¼¼°èÀûÀ¸·Î ´ë»çÁõÈıºÀÇ Áõ°¡¿Í Áö¹æ°£ ÁúȯÀÌ Á¶¿ëÇÏÁö¸¸ ½É°¢ÇÑ °Ç°­ À§ÇùÀ̶ó´Â ÀνÄÀÌ ³ô¾ÆÁü¿¡ µû¶ó È¿°úÀûÀÎ Áö¹æ°£ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ ¸ðµç ¿¬·É´ë¿Í Áö¿ª¿¡¼­ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. °ú°Å¿¡´Â ÁÖ·Î ³ëÀÎÀ̳ª ¾ËÄÚ¿Ã ³²¿ëÀÇ º´·ÂÀÌ ÀÖ´Â »ç¶÷µéÀÌ ÁÖ·Î ¾Î´Â ÁúȯÀ¸·Î ¿©°ÜÁ³À¸³ª, ¼Ò¾Æ ºñ¸¸°ú ÁÂ½Ä »ýȰ½À°üÀÇ Áõ°¡·Î ÀÎÇØ ¼Ò¾Æ ¹× û¼Ò³âÀ» Æ÷ÇÔÇÑ ÀþÀº ¿¬·ÉÃþ¿¡¼­µµ Áö¹æ°£ Áø´ÜÀ» ¹Þ´Â °æ¿ì°¡ ¸¹¾ÆÁö°í ÀÖ½À´Ï´Ù. ¹Ì±¹, µ¶ÀÏ, ÀϺ», ¿µ±¹ µî °í¼Òµæ ±¹°¡¿¡¼­´Â °¡°ø½Äǰ ¼Òºñ¿Í ´ç´¢º´ À¯º´·üÀÌ ³ô¾Æ NAFLD°¡ ¸¸¼º °£ÁúȯÀÇ ÁÖ¿ä ¿øÀÎ Áß Çϳª·Î ²ÅÈ÷°í ÀÖ½À´Ï´Ù. ¹Ý¸é, Àεµ, Áß±¹, ºê¶óÁú, Áßµ¿ ±¹°¡ µî ½ÅÈï±¹¿¡¼­´Â µµ½ÃÈ­, ½Ä»ýȰ º¯È­, ¶óÀÌÇÁ½ºÅ¸ÀÏÀÇ º¯È­·Î ÀÎÇØ NAFLD ȯÀÚ°¡ ºü¸£°Ô Áõ°¡Çϰí ÀÖÀ¸¸ç, Á¾Á¾ ÀÇ·á ½Ã½ºÅÛ Á¤ºñº¸´Ù ´õ ºü¸£°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Àα¸Åë°èÇÐÀû º¯È­´Â Á¶±â °ËÁø ÇÁ·ÎÅäÄÝ Ã¤ÅÃ, °øÁß º¸°Ç ±³À°À» À§ÇÑ ÀÚ¿ø ¹èºÐ, Ä¡·á Á¢±Ù¼º È®´ë µî ÀÇ·á ¼­ºñ½º Á¦°øÀÚ¿¡°Ô Å« ¾Ð¹ÚÀ» °¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °øÁߺ¸°Ç Ä·ÆäÀÎ, ¿Â¶óÀÎ Ç÷§Æû, ÀÇ»çµéÀÇ ¿ËÈ£ Ȱµ¿À» ÅëÇØ ÀÎÁöµµ°¡ ³ô¾ÆÁü¿¡ µû¶ó Áø´Ü Æò°¡ ¹× Ä¡·á ÁßÀ縦 ¿äûÇÏ´Â »ç¶÷µéÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¦¾à»ç ¹× ÀÇ·á ±â°üµéÀº ÀÌ·¯ÇÑ È¯ÀÚ ¼ö Áõ°¡¿Í Áö¸®Àû È®»ê¿¡ ´ëÀÀÇϱâ À§ÇØ ÀÓ»ó ¿¬±¸, Áö¿ª ÆÄÆ®³Ê½Ê, ±³À° ¹× È«º¸ Ȱµ¿À» °­È­ÇÏ´Â µî ´Ù¾çÇÑ ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼¼°è Áúº´ ºÎ´ãÀÇ Áõ°¡´Â Ä¡·á ½ÃÀåÀ» È®´ëÇÒ »Ó¸¸ ¾Æ´Ï¶ó, ÀÌÇØ°ü°èÀÚ °£ÀÇ Çù·ÂÀ» ÃËÁøÇϰí È®Àå °¡´ÉÇϰí Áö¼Ó°¡´ÉÇÑ ¼Ö·ç¼ÇÀ» °³¹ßÇϵµ·Ï À¯µµÇϰí ÀÖ½À´Ï´Ù.

¼¼°è Áö¹æ°£ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?

Áö¹æ°£ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ÀÓ»óÀû, °æÁ¦Àû, ±â¼úÀû, Á¤Ã¥Àû, ±â¼úÀû, Á¤Ã¥Àû µî ´Ù¾çÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ¸ðµÎ ÀÌ °Ç°­ ¹®Á¦¸¦ ÇØ°áÇϱâ À§ÇÑ ½Ã±Þ¼º°ú º¹À⼺À» ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎÀº ºñ¸¸, ´ç´¢º´, ´ë»çÁõÈıº°ú °°Àº »ýȰ½À°üº´ÀÇ È®»êÀÌ ½ÉÈ­µÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ¸ðµÎ Áö¹æ°£ ÁúȯÀÇ ¹ßº´ ¹× ÁøÇà°ú ¹ÐÁ¢ÇÑ °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ÀǾàǰ °³¹ß ¹× Àӻ󿬱¸¿¡ ´ëÇÑ ÅõÀÚ°¡ Ȱ¹ßÈ÷ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿ Ž»ö, ¿µ»ó ±â¼ú, ÀΰøÁö´ÉÀÇ ¹ßÀüÀ¸·Î Á¶±â Áø´Ü, À§Çè °èÃþÈ­, Ä¡·á ÃÖÀûÈ­°¡ °¡´ÉÇØÁ® ȯÀÚ °á°ú¿Í ÀÇ·á ½Ã½ºÅÛÀÇ È¿À²¼ºÀÌ Å©°Ô Çâ»óµÇ°í ÀÖ½À´Ï´Ù. °Ç°­ º¸Çè Á¦°øÀÚ¿Í °ø°ø ÀÇ·á ½Ã½ºÅÛÀº Ä¡·áµÇÁö ¾ÊÀº Áö¹æ°£ ÁúȯÀÌ Àå±âÀûÀÎ ºñ¿ë ºÎ´ãÀ» ÃÊ·¡ÇÑ´Ù´Â »ç½ÇÀ» Á¡Á¡ ´õ ¸¹ÀÌ ÀνÄÇϰí ÀÖÀ¸¸ç, ºñħ½ÀÀû °Ë»ç ¹× »õ·Î¿î Ä¡·á¹ý¿¡ ´ëÇÑ Æø³ÐÀº »óȯÀ» Àå·ÁÇϰí ÀÖ½À´Ï´Ù. ±ÔÁ¦ ´ç±¹ ¿ª½Ã ±ä±ÞÇÑ °³ÀÔÀÇ Çʿ伺¿¡ µû¶ó À¯¸ÁÇÑ ½Å¾à Èĺ¸¹°ÁúÀÇ ½ÂÀÎ ÀÏÁ¤À» ¾Õ´ç±â°í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À Á¦¾à»ç, Çаè, Áø´Ü ±â¾÷ °£ÀÇ Àü·«Àû Á¦ÈÞ´Â Çõ½Å ÆÄÀÌÇÁ¶óÀÎÀ» È®ÀåÇÏ°í »õ·Î¿î Ä¡·áÁ¦ÀÇ ½ÃÀå Ãâ½Ã ½Ã°£À» ´ÜÃàÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀÏ¹Ý ´ëÁßÀÇ ÀÎ½Ä °³¼±, ȯÀÚ Áö¿ø Ȱµ¿, µðÁöÅÐ Âü¿© Ç÷§ÆûÀ¸·Î ÀÎÇØ °³ÀÎÀÌ °£ °Ç°­ °ü¸®¿¡ Àû±ØÀûÀÎ ¿ªÇÒÀ» ÇÒ ¼ö ÀÖ´Â ÈûÀÌ °­È­µÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀεéÀÌ °áÇÕµÇ¾î ¼¼°è Áö¹æ°£ Ä¡·á ½ÃÀåÀº Áö¼ÓÀûÀ¸·Î Å©°Ô ¼ºÀåÇϰí ÀÖÀ¸¸ç, °ú°Å¿¡´Â °£°úµÇ¾ú´ø ÁúȯÀÌ 21¼¼±â ÀÇ·áÀÇ ÁÖ¿ä °ü½É»ç·Î º¯¸ðÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

ÀǾàǰ(Ä¡¾ÆÁ¹¸®µòµð¿Â, ºñŸ¹Î E, ¸ÞÆ®Æ÷¸£¹Î ½ºÅ¸Æ¾, ´Ù°¡ºÒÆ÷È­Áö¹æ»ê, ¾ÈÁö¿ÀÅٽмö¿ëü ±æÇ×Á¦, ÆæÅå½ÃÇʸ°), ÃÖÁ¾»ç¿ëÀÚ(º´¿ø, Ŭ¸®´Ð)

Á¶»ç ´ë»ó ±â¾÷ »ç·Ê(ÃÑ 42°³»ç)

AI ÅëÇÕ

¿ì¸®´Â °ËÁõµÈ Àü¹®°¡ ÄÁÅÙÃ÷¿Í AI ÅøÀ» ÅëÇØ ½ÃÀå Á¤º¸¿Í °æÀï Á¤º¸¸¦ Çõ½ÅÇϰí ÀÖ½À´Ï´Ù.

Global Industry Analysts´Â LLM ¹× »ê¾÷º° SLM Äõ¸®¸¦ µû¸£´Â ´ë½Å ºñµð¿À ±â·Ï, ºí·Î±×, °Ë»ö ¿£Áø Á¶»ç, ¹æ´ëÇÑ ¾çÀÇ ±â¾÷, Á¦Ç°/¼­ºñ½º, ½ÃÀå µ¥ÀÌÅÍ µî ¼¼°è Àü¹®°¡·ÎºÎÅÍ ¼öÁýÇÑ ÄÁÅÙÃ÷ ¸®Æ÷ÁöÅ丮¸¦ ±¸ÃàÇß½À´Ï´Ù.

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ¸ÅÃâ¿ø°¡(COGS) Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Fatty Liver Treatment Market to Reach US$23.1 Billion by 2030

The global market for Fatty Liver Treatment estimated at US$18.7 Billion in the year 2024, is expected to reach US$23.1 Billion by 2030, growing at a CAGR of 3.6% over the analysis period 2024-2030. Thiazolidinedione, one of the segments analyzed in the report, is expected to record a 3.0% CAGR and reach US$6.6 Billion by the end of the analysis period. Growth in the Vitamin E segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.1 Billion While China is Forecast to Grow at 6.5% CAGR

The Fatty Liver Treatment market in the U.S. is estimated at US$5.1 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.6 Billion by the year 2030 trailing a CAGR of 6.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.0% CAGR.

Global Fatty Liver Treatment Market - Key Trends & Drivers Summarized

Why Is Fatty Liver Disease Becoming a Major Global Health Concern Necessitating Targeted Treatments?

Fatty liver disease, encompassing both non-alcoholic fatty liver disease (NAFLD) and alcoholic fatty liver disease (AFLD), has emerged as a critical public health issue worldwide due to its rising prevalence, close association with metabolic disorders, and potential to progress into more severe hepatic conditions such as steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Modern sedentary lifestyles, poor dietary habits, rising obesity rates, and increased incidence of type 2 diabetes have all contributed to an alarming increase in fatty liver diagnoses, particularly NAFLD, which now affects up to 25% of the global population. Despite its prevalence, fatty liver disease often remains undiagnosed in its early stages due to the lack of symptoms, allowing progression without intervention. As a result, there is growing urgency to develop and implement effective treatment options, ranging from lifestyle modification programs and pharmacologic interventions to surgical solutions in severe cases. Moreover, the potential link between fatty liver disease and cardiovascular complications further elevates its medical significance, making its treatment not only essential for liver health but also for reducing broader systemic risks. As awareness improves among both clinicians and patients, early diagnosis and tailored treatment strategies are becoming crucial in slowing disease progression and reducing long-term healthcare burdens associated with chronic liver diseases.

How Are Therapeutic Innovations Transforming the Management of Fatty Liver Disease?

Advances in medical research and pharmaceutical development are rapidly transforming the landscape of fatty liver treatment, offering hope for more effective disease management and long-term outcomes. Traditionally, lifestyle modifications-such as dietary changes, increased physical activity, and weight loss-have served as the first line of defense against fatty liver disease. However, the limitations of patient adherence and the lack of consistent outcomes have accelerated the pursuit of pharmacologic solutions. Several drug candidates targeting key mechanisms in lipid metabolism, inflammation, fibrosis, and insulin resistance are currently in clinical trials, including FXR agonists, PPAR agonists, and GLP-1 receptor agonists. Drugs like pioglitazone and vitamin E have shown modest success in certain patient subgroups, while newer agents such as obeticholic acid and resmetirom are demonstrating promising results in reducing liver fat content and fibrosis in NASH (non-alcoholic steatohepatitis) patients. In addition to monotherapies, combination therapies that simultaneously address multiple pathogenic pathways are gaining traction as potentially more effective interventions. The integration of non-invasive diagnostic tools such as FibroScan, MRI-PDFF, and serum biomarkers is also enhancing treatment monitoring and enabling personalized care plans. Moreover, digital health tools and mobile health apps are helping patients maintain lifestyle changes through behavior tracking and telemedicine support. These therapeutic innovations are not only improving clinical outcomes but are also making fatty liver treatment more accessible, evidence-based, and adaptable to patient-specific conditions.

Why Is Demand for Fatty Liver Treatments Growing Across Demographics and Geographies?

The demand for effective fatty liver treatments is increasing across all age groups and regions, fueled by the global rise of metabolic syndromes and the growing recognition of fatty liver disease as a silent but serious health threat. While once considered a condition affecting primarily older adults or individuals with a history of alcohol misuse, fatty liver disease is now being diagnosed in younger populations-including children and adolescents-largely due to increasing rates of childhood obesity and sedentary lifestyles. In high-income countries like the U.S., Germany, Japan, and the U.K., where processed food consumption and diabetes prevalence are high, NAFLD has become one of the leading causes of chronic liver disease. Meanwhile, emerging economies such as India, China, Brazil, and countries in the Middle East are witnessing a rapid surge in cases due to urbanization, dietary shifts, and lifestyle transitions-often outpacing healthcare system preparedness. These demographic shifts are creating immense pressure on healthcare providers to adopt early screening protocols, allocate resources for public health education, and expand treatment access. Additionally, rising awareness through public health campaigns, online platforms, and physician advocacy is prompting more individuals to seek diagnostic evaluations and therapeutic interventions. Pharmaceutical companies and healthcare institutions are responding by ramping up clinical research, regional partnerships, and educational outreach to address this growing and geographically widespread patient population. This global rise in disease burden is not only expanding the treatment market but also encouraging collaboration across stakeholders to develop scalable and sustainable solutions.

What Are the Primary Drivers Fueling the Growth of the Fatty Liver Treatment Market Worldwide?

The growth of the fatty liver treatment market is being driven by a multifaceted set of clinical, economic, technological, and policy-related factors that together reflect the urgency and complexity of managing this rising health challenge. A key driver is the escalating prevalence of lifestyle-related diseases such as obesity, diabetes, and metabolic syndrome, all of which are strongly linked to the onset and progression of fatty liver disease. The lack of FDA-approved therapies specifically for NAFLD and NASH has created a massive unmet medical need, fueling robust investment in drug development and clinical research. Advances in biomarker discovery, imaging technologies, and artificial intelligence are enabling earlier diagnosis, risk stratification, and treatment optimization, significantly enhancing patient outcomes and health system efficiency. Health insurance providers and public healthcare systems are increasingly recognizing the long-term cost burden of untreated fatty liver disease, prompting broader reimbursement for non-invasive testing and emerging therapies. Regulatory agencies are also accelerating approval timelines for promising drug candidates, spurred by the urgent need for intervention. Strategic collaborations between biopharmaceutical firms, academic institutions, and diagnostic companies are expanding the innovation pipeline and reducing time-to-market for novel treatments. Furthermore, increased public awareness, patient advocacy efforts, and digital engagement platforms are empowering individuals to take a proactive role in liver health management. Combined, these factors are setting the stage for significant and sustained expansion of the global fatty liver treatment market, transforming a once-overlooked condition into a major focus of 21st-century medicine.

SCOPE OF STUDY:

The report analyzes the Fatty Liver Treatment market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug (Thiazolidinedione, Vitamin E, Metformin Statins, Polyunsaturated Fatty Acids, Angiotensin Receptor Blockers, Pentoxifylline); End-Use (Hospitals, Clinics)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â